THERAMetrics holding AG(SIX: TMX) and its fully owned subsidiary, Pierrel Research International AG, discuss Strength in Numbers

Stans, Switzerland, February 13, 2014 - Ms Maxime Stevens, Group CEO of Pierrel Research International AG proudly observes that as the pharmaceutical and biotech markets increase and renew their loyalty and confidence in Pierrel Research International AG, so does the recruitment marketplace. The new Senior Management team of PRINT continues to grow to near completion, with highly experienced and talented leaders joining the already committed taskforce, rebuilding and shaping the future of the Group. The Group has undergone considerable restructure, introducing new, integrated and efficient systems and strategies; all implemented to further enhance delivery of service, and reduce given timelines of clinical trials. Linear, responsive and accountable organization, coupled with the on-going implementation of improved strategy and processes, is reflecting increased robust pipelines, and a continued growth of revenue backlog that extends through to 2017. The steady increase of awarded new contracts reflects the conviction of new and existing Sponsors that the Group delivers a successful clinical trial with reliable results, within and often reducing given timelines. This has an immediate financial impact on the Sponsor, reducing costs of a given clinical trial significantly. About THERAMetrics THERAMetrics holding AG is a tech-based Contract Research & Development Organization dedicated to provide a full range of technological solutions through the entire value chain of drug discovery and development. The company, listed at the SIX Swiss Exchange (TMX) and located in Stans (Switzerland). For further information please contact: THERAMetrics holding AG Investor and External Relations Tel.: +41 79 285 37 81 [email protected] www.therametrics.com Disclaimer This communication expressly or implicitly contains certain forward-looking statements concerning THERAMetrics holding AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of THERAMetrics holding AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. THERAMetrics holding AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

Suggested Articles

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.

WIRB-Copernicus Group’s clinical services division bought out trial consultancy firm Waife & Associates as it looks to boost its management services.